

Hiroto Inaba

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7470889/publications.pdf>

Version: 2024-02-01

172
papers

8,039
citations

61984

43
h-index

54911

84
g-index

173
all docs

173
docs citations

173
times ranked

10337
citing authors

#	ARTICLE	IF	CITATIONS
1	Comprehensive analysis of dose intensity of acute lymphoblastic leukemia chemotherapy. <i>Haematologica</i> , 2022, 107, 371-380.	3.5	5
2	Impact of High Disease Burden on Survival in Pediatric Patients with B-ALL Treated with Tisagenlecleucel. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 73.e1-73.e9.	1.2	20
3	Integrated Genomic Analysis Identifies <i>UBTF</i> Tandem Duplications as a Recurrent Lesion in Pediatric Acute Myeloid Leukemia. <i>Blood Cancer Discovery</i> , 2022, 3, 194-207.	5.0	38
4	Changes in body mass index, weight, and height in children with acute myeloid leukemia and the associations with outcome. <i>Blood Advances</i> , 2022, 6, 2824-2834.	5.2	3
5	Preclinical and Pilot Study of Type I FLT3 Tyrosine Kinase Inhibitor, Crenolanib, with Sorafenib in Acute Myeloid Leukemia and <i>FLT3</i> -Internal Tandem Duplication. <i>Clinical Cancer Research</i> , 2022, 28, 2536-2546.	7.0	3
6	Simultaneous monitoring of disease and microbe dynamics through plasma DNA sequencing in pediatric patients with acute lymphoblastic leukemia. <i>Science Advances</i> , 2022, 8, eabj1360.	10.3	2
7	Preferential expansion of CD8+ CD19-CAR T cells postinfusion and the role of disease burden on outcome in pediatric B-ALL. <i>Blood Advances</i> , 2022, 6, 5737-5749.	5.2	20
8	Amino acid stress response genes promote L-asparaginase resistance in pediatric acute lymphoblastic leukemia. <i>Blood Advances</i> , 2022, 6, 3386-3397.	5.2	8
9	Bone mineral density (BMD) deficits in adult survivors of childhood cancer: Attributable risks and long-term consequences. <i>Journal of Clinical Oncology</i> , 2022, 40, e22021-e22021.	1.6	0
10	Longitudinal Trajectories of Neurocognitive Functioning in Childhood Acute Lymphoblastic Leukemia. <i>Journal of Pediatric Psychology</i> , 2021, 46, 168-178.	2.1	10
11	Ultrasound has limited diagnostic utility in children with acute lymphoblastic leukemia developing pancreatitis. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28730.	1.5	7
12	Late outcomes in survivors of childhood acute myeloid leukemia: a report from the St. Jude Lifetime Cohort Study. <i>Leukemia</i> , 2021, 35, 2258-2273.	7.2	10
13	Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia. <i>Nature Cancer</i> , 2021, 2, 284-299.	13.2	70
14	Preventing weight gain in children with acute lymphoblastic leukemia by early nutritional intervention. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28965.	1.5	0
15	Clinical characteristics and outcomes of B-ALL with ZNF384 rearrangements: a retrospective analysis by the Ponte di Legno Childhood ALL Working Group. <i>Leukemia</i> , 2021, 35, 3272-3277.	7.2	40
16	Association between obesity and neurocognitive function in survivors of childhood acute lymphoblastic leukemia treated only with chemotherapy. <i>Cancer</i> , 2021, 127, 3202-3213.	4.1	4
17	Advances in the Diagnosis and Treatment of Pediatric Acute Lymphoblastic Leukemia. <i>Journal of Clinical Medicine</i> , 2021, 10, 1926.	2.4	86
18	Class II Human Leukocyte Antigen Variants Associate With Risk of Pegaspargase Hypersensitivity. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 794-802.	4.7	7

#	ARTICLE	IF	CITATIONS
19	Clinical Significance of Novel Subtypes of Acute Lymphoblastic Leukemia in the Context of Minimal Residual Disease—Directed Therapy. <i>Blood Cancer Discovery</i> , 2021, 2, 326-337.	5.0	71
20	Testicular involvement of acute lymphoblastic leukemia in children and adolescents: Diagnosis, biology, and management. <i>Cancer</i> , 2021, 127, 3067-3081.	4.1	18
21	Clinicopathologic and prognostic features of TdT-negative pediatric B-lymphoblastic leukemia. <i>Modern Pathology</i> , 2021, 34, 2050-2054.	5.5	5
22	Pharmacodynamics of cerebrospinal fluid asparagine after asparaginase. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 88, 655-664.	2.3	5
23	Reduced intensity chemotherapy with tyrosine kinase inhibitor and blinatumomab in a pediatric patient with Philadelphia chromosome—positive ALL and mechanical heart valves. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28924.	1.5	0
24	Clofarabine-Based Chemotherapy for KMT2Ar Infantile Acute Lymphoblastic Leukemia. <i>Blood</i> , 2021, 138, 3406-3406.	1.4	1
25	Clinical Features and Cytoreduction Therapy in Children with Newly Diagnosed Acute Myeloid Leukemia and Hyperleukocytosis. <i>Blood</i> , 2021, 138, 2295-2295.	1.4	0
26	Amino Acid Stress Response Genes Promote L-Asparaginase Resistance in Pediatric Acute Lymphoblastic Leukemia. <i>Blood</i> , 2021, 138, 3304-3304.	1.4	0
27	Integrated Genomic Analysis Identifies LIBTF Tandem Duplications As a Subtype-Defining Lesion in Pediatric Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, LBA-4-LBA-4.	1.4	0
28	Pediatric Cardio-Oncology Medicine: A New Approach in Cardiovascular Care. <i>Children</i> , 2021, 8, 1200.	1.5	2
29	Mixed—phenotype acute leukemia: A cohort and consensus research strategy from the Children—s Oncology Group Acute Leukemia of Ambiguous Lineage Task Force. <i>Cancer</i> , 2020, 126, 593-601.	4.1	32
30	Asparaginase formulation impacts hypertriglyceridemia during therapy for acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28040.	1.5	38
31	Intensive but tender care for infant ALL. <i>Blood</i> , 2020, 136, 1797-1798.	1.4	0
32	Evaluation of Chest Radiographs of Children with Newly Diagnosed Acute—Lymphoblastic Leukemia. <i>Journal of Pediatrics</i> , 2020, 223, 120-127.e3.	1.8	1
33	Safety, pharmacokinetics, and pharmacodynamics of panobinostat in children, adolescents, and young adults with relapsed acute myeloid leukemia. <i>Cancer</i> , 2020, 126, 4800-4805.	4.1	12
34	Predicting success of desensitization after pegaspargase allergy. <i>Blood</i> , 2020, 135, 71-75.	1.4	20
35	Integrative genomic analysis of B—lymphoblastic lymphoma with intrachromosomal amplification of chromosome 21. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28357.	1.5	2
36	Whole—joint magnetic resonance imaging to assess osteonecrosis in pediatric patients with acute lymphoblastic lymphoma. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28336.	1.5	6

#	ARTICLE	IF	CITATIONS
37	Integrative genomic analyses reveal mechanisms of glucocorticoid resistance in acute lymphoblastic leukemia. <i>Nature Cancer</i> , 2020, 1, 329-344.	13.2	44
38	Incidence of hip and knee osteonecrosis and their associations with bone mineral density in children with acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2020, 189, e177-e181.	2.5	9
39	Metabolic Acidosis in a Pediatric Patient with Leukemia and Fungal Infection. <i>Clinical Chemistry</i> , 2020, 66, 518-522.	3.2	2
40	Higher plasma asparaginase activity after intramuscular than intravenous Erwinia asparaginase. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28244.	1.5	5
41	Allogeneic Hematopoietic Cell Transplantation Is Critical to Maintain Remissions after CD19-CAR T-Cell Therapy for Pediatric ALL: A Single Center Experience. <i>Blood</i> , 2020, 136, 39-40.	1.4	3
42	Pediatric acute lymphoblastic leukemia. <i>Haematologica</i> , 2020, 105, 2524-2539.	3.5	313
43	Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 81-112.	4.9	102
44	Hypertension is a modifiable risk factor for osteonecrosis in acute lymphoblastic leukemia. <i>Blood</i> , 2019, 134, 983-986.	1.4	12
45	Uncovering the Genomic Landscape in Newly Diagnosed and Relapsed Pediatric Cytogenetically Normal FLT3-ITD AML. <i>Clinical and Translational Science</i> , 2019, 12, 641-647.	3.1	12
46	Clofarabine Can Replace Anthracyclines and Etoposide in Remission Induction Therapy for Childhood Acute Myeloid Leukemia: The AML08 Multicenter, Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 2072-2081.	1.6	34
47	Improved CNS Control of Childhood Acute Lymphoblastic Leukemia Without Cranial Irradiation: St Jude Total Therapy Study 16. <i>Journal of Clinical Oncology</i> , 2019, 37, 3377-3391.	1.6	169
48	Sorafenib Population Pharmacokinetics and Skin Toxicities in Children and Adolescents with Refractory/Relapsed Leukemia or Solid Tumor Malignancies. <i>Clinical Cancer Research</i> , 2019, 25, 7320-7330.	7.0	14
49	Association Between Anesthesia Exposure and Neurocognitive and Neuroimaging Outcomes in Long-term Survivors of Childhood Acute Lymphoblastic Leukemia. <i>JAMA Oncology</i> , 2019, 5, 1456.	7.1	77
50	Treatment response and outcome of children with T-cell acute lymphoblastic leukemia expressing the gamma-delta T-cell receptor. <i>Oncoimmunology</i> , 2019, 8, 1599637.	4.6	12
51	Antibodies Predict Pegaspargase Allergic Reactions and Failure of Rechallenge. <i>Journal of Clinical Oncology</i> , 2019, 37, 2051-2061.	1.6	61
52	A high-throughput screen indicates gemcitabine and JAK inhibitors may be useful for treating pediatric AML. <i>Nature Communications</i> , 2019, 10, 2189.	12.8	26
53	Obesity and height in children and adolescents with acute lymphoblastic leukemia and its future management. <i>Oncotarget</i> , 2019, 10, 1233-1234.	1.8	2
54	Absolute count of leukemic blasts in cerebrospinal fluid as detected by flow cytometry is a relevant prognostic factor in children with acute lymphoblastic leukemia. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1331-1339.	2.5	24

#	ARTICLE	IF	CITATIONS
55	A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemia. , 2019, 7, 81.		74
56	Leukemic presentation of ALK-positive anaplastic large cell lymphoma with a novel partner, poly(A) binding protein cytoplasmic 1 (PABPC1), responding to single-agent crizotinib. Haematologica, 2019, 104, e218-e221.	3.5	14
57	Bloodstream infections exacerbate incidence and severity of symptomatic glucocorticoid-induced osteonecrosis. Pediatric Blood and Cancer, 2019, 66, e27669.	1.5	11
58	Immunotherapy in pediatric acute lymphoblastic leukemia. Cancer and Metastasis Reviews, 2019, 38, 595-610.	5.9	65
59	Acute Lymphoblastic Leukemia with Zinc-Finger Protein 384 (ZNF384)-Related Rearrangements: A Retrospective Analysis from the Ponte Di Legno Childhood ALL Working Group. Blood, 2019, 134, 652-652.	1.4	6
60	Clinical germline diagnostic exome sequencing for hereditary cancer: Findings within novel candidate genes are prevalent. Cancer Genetics, 2018, 224-225, 12-20.	0.4	7
61	Bone mineral density in children with acute lymphoblastic leukemia. Cancer, 2018, 124, 1025-1035.	4.1	21
62	International cooperative study identifies treatment strategy in childhood ambiguous lineage leukemia. Blood, 2018, 132, 264-276.	1.4	70
63	Adverse Effects of Intravenous Vancomycin-Based Prophylaxis during Therapy for Pediatric Acute Myeloid Leukemia. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	5
64	Association of Bacteremic Sepsis With Long-term Neurocognitive Dysfunction in Pediatric Patients With Acute Lymphoblastic Leukemia. JAMA Pediatrics, 2018, 172, 1092.	6.2	21
65	Peripheral neuropathy in children and adolescents treated for cancer. The Lancet Child and Adolescent Health, 2018, 2, 744-754.	5.6	41
66	Changes in body mass index, height, and weight in children during and after therapy for acute lymphoblastic leukemia. Cancer, 2018, 124, 4248-4259.	4.1	43
67	The genetic basis and cell of origin of mixed phenotype acute leukaemia. Nature, 2018, 562, 373-379.	27.8	236
68	Pegaspargase Allergic Reactions Are Related to Anti-Pegaspargase Antibodies and to Intensity of Intrathecal Therapy. Blood, 2018, 132, 2697-2697.	1.4	2
69	Traumatic and Bloody Lumbar Puncture at Diagnosis in Children with Acute Lymphoblastic Leukemia: A St. Jude Total XV and Total XVI Cohort Study. Blood, 2018, 132, 1380-1380.	1.4	0
70	The Effect of Asparaginase on Serum Triglycerides during Therapy for Acute Lymphoblastic Leukemia. Blood, 2018, 132, 2665-2665.	1.4	0
71	Transcriptome profiling of patient derived xenograft models established from pediatric acute myeloid leukemia patients confirm maintenance of FLT3-ITD mutation. Leukemia and Lymphoma, 2017, 58, 247-250.	1.3	5
72	The effects of inherited NUDT15 polymorphisms on thiopurine active metabolites in Japanese children with acute lymphoblastic leukemia. Pharmacogenetics and Genomics, 2017, 27, 236-239.	1.5	63

#	ARTICLE	IF	CITATIONS
73	Genetics of pleiotropic effects of dexamethasone. <i>Pharmacogenetics and Genomics</i> , 2017, 27, 294-302.	1.5	17
74	Decreased relapsed rate and treatment-related mortality contribute to improved outcomes for pediatric acute myeloid leukemia in successive clinical trials. <i>Cancer</i> , 2017, 123, 3791-3798.	4.1	34
75	Levofloxacin Prophylaxis During Induction Therapy for Pediatric Acute Lymphoblastic Leukemia. <i>Clinical Infectious Diseases</i> , 2017, 65, 1790-1798.	5.8	62
76	Asparaginase-associated pancreatitis in childhood acute lymphoblastic leukaemia: an observational Ponte di Legno Toxicity Working Group study. <i>Lancet Oncology</i> , The, 2017, 18, 1238-1248.	10.7	87
77	Integration of Next-Generation Sequencing to Treat Acute Lymphoblastic Leukemia with Targetable Lesions: The St. Jude Children's Research Hospital Approach. <i>Frontiers in Pediatrics</i> , 2017, 5, 258.	1.9	62
78	Hypoxia-induced upregulation of BMX kinase mediates therapeutic resistance in acute myeloid leukemia. <i>Journal of Clinical Investigation</i> , 2017, 128, 369-380.	8.2	39
79	Efficacy of ALL Therapy for WHO2016-Defined Mixed Phenotype Acute Leukemia: A Report from the Children's Oncology Group. <i>Blood</i> , 2017, 130, 883-883.	1.4	2
80	Clinical manifestations of sepsis during nonfatal bacteremia in pediatric patients undergoing therapy for acute lymphoblastic leukemia. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.9	0
81	The Role of Leukapheresis in the Current Management of Hyperleukocytosis in Newly Diagnosed Childhood Acute Lymphoblastic Leukemia. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1546-1551.	1.5	29
82	NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity. <i>Nature Genetics</i> , 2016, 48, 367-373.	21.4	389
83	Multikinase Inhibitors Induce Cutaneous Toxicity through OAT6-Mediated Uptake and MAP3K7-Driven Cell Death. <i>Cancer Research</i> , 2016, 76, 117-126.	0.9	36
84	Pilot Study of Combined Type I FLT3 Tyrosine Kinase Inhibitor, Crenolanib with Sorafenib in Pediatric Patients with Relapsed/Refractory FLT3+Ve AML. <i>Blood</i> , 2016, 128, 3937-3937.	1.4	3
85	Genomic Landscape of Pediatric Mixed Phenotype Acute Leukemia. <i>Blood</i> , 2016, 128, 454-454.	1.4	4
86	Acute Leukemia of Ambiguous Lineage: A Comprehensive Survival Analysis Enables Designing New Treatment Strategies. <i>Blood</i> , 2016, 128, 584-584.	1.4	2
87	Genomic Profiling Identifies Novel Mutations and Fusion Genes in Newly Diagnosed and Relapsed Pediatric FLT3-ITD-Positive AML. <i>Blood</i> , 2016, 128, 2838-2838.	1.4	0
88	Asparaginase-Associated Pancreatitis in Childhood Acute Lymphoblastic Leukemia: A Ponte Di Legno Toxicity Working Group Report on Clinical Presentation and Outcome. <i>Blood</i> , 2016, 128, 585-585.	1.4	1
89	Outcome of children with hypodiploid ALL treated with risk-directed therapy based on MRD levels. <i>Blood</i> , 2015, 126, 2896-2899.	1.4	76
90	Heterogeneous cytogenetic subgroups and outcomes in childhood acute megakaryoblastic leukemia: a retrospective international study. <i>Blood</i> , 2015, 126, 1575-1584.	1.4	69

#	ARTICLE	IF	CITATIONS
91	Germline ETV6 Mutations Confer Susceptibility to Acute Lymphoblastic Leukemia and Thrombocytopenia. <i>PLoS Genetics</i> , 2015, 11, e1005262.	3.5	128
92	Utility of Early Screening Magnetic Resonance Imaging for Extensive Hip Osteonecrosis in Pediatric Patients Treated With Glucocorticoids. <i>Journal of Clinical Oncology</i> , 2015, 33, 610-615.	1.6	56
93	Natural killer cell therapy in children with relapsed leukemia. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1468-1472.	1.5	39
94	Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study. <i>Lancet Oncology</i> , The, 2015, 16, 465-474.	10.7	177
95	The role of ^{18}F -FDG-PET/CT in the evaluation of residual disease in paediatric non-Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2015, 168, 845-853.	2.5	37
96	Skeletal, neuromuscular and fitness impairments among children with newly diagnosed acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2015, 56, 1004-1011.	1.3	70
97	Prognostic factors in children with acute myeloid leukaemia and excellent response to remission induction therapy. <i>British Journal of Haematology</i> , 2015, 168, 94-101.	2.5	31
98	Abstract 2033: Germline mutations in ETV6 confer risk of thrombocytopenia and acute lymphocytic leukemia. , 2015, , .		1
99	Acute Leukemias of Ambiguous Lineage; Study on 247 Pediatric Patients. <i>Blood</i> , 2015, 126, 252-252.	1.4	4
100	Acute Appendicitis in Children with Leukemia: Unique Diagnostic Process, Management, and Outcome. <i>Blood</i> , 2015, 126, 4872-4872.	1.4	3
101	High Incidence of Induction Failure and Poor Outcome in Patients with Gamma Delta T Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015, 126, 1421-1421.	1.4	2
102	Body Mass Index Is Not Associated with Early Treatment Response or Clinical Outcome in Children with Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015, 126, 1299-1299.	1.4	0
103	t(6;9)(p22;q34)/DEK-NUP214-rearranged pediatric myeloid leukemia: an international study of 62 patients. <i>Haematologica</i> , 2014, 99, 865-872.	3.5	77
104	Feasibility, efficacy, and adverse effects of outpatient antibacterial prophylaxis in children with acute myeloid leukemia. <i>Cancer</i> , 2014, 120, 1985-1992.	4.1	53
105	Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia. <i>Cancer</i> , 2014, 120, 1514-1519.	4.1	58
106	Definition of cure in childhood acute myeloid leukemia. <i>Cancer</i> , 2014, 120, 2490-2496.	4.1	12
107	Tyrosine Kinase Inhibitor (TKI) Combination Scheduling Impacts Secondary FLT3 Tyrosine Kinase Domain (TKD) Mutation Profiles in a Xenograft Model of FLT3-ITD+ Acute Myeloid Leukemia (AML). <i>Blood</i> , 2014, 124, 3620-3620.	1.4	0
108	Pediatric Acute Megakaryoblastic Leukemia without Down Syndrome: A Retrospective Study by the International Berlin-Frankfurt-Munster Study Group (I-BFMMSG). <i>Blood</i> , 2014, 124, 3670-3670.	1.4	0

#	ARTICLE	IF	CITATIONS
109	Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia. <i>Cancer</i> , 2013, 119, 4036-4043.	4.1	41
110	Prognostic impact of absolute lymphocyte counts at the end of remission induction in childhood acute lymphoblastic leukemia. <i>Cancer</i> , 2013, 119, 2061-2066.	4.1	27
111	Alternative formulations of sorafenib for use in children. <i>Pediatric Blood and Cancer</i> , 2013, 60, 1642-1646.	1.5	9
112	Acute lymphoblastic leukaemia. <i>Lancet</i> , The, 2013, 381, 1943-1955.	13.7	879
113	Sequential administration of methotrexate and asparaginase in relapsed or refractory pediatric acute myeloid leukemia. <i>Pediatric Blood and Cancer</i> , 2013, 60, 1161-1164.	1.5	22
114	Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD ⁺ Positive Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2013, 19, 5758-5768.	7.0	87
115	Crenolanib is active against models of drug-resistant FLT3-ITD ⁺ positive acute myeloid leukemia. <i>Blood</i> , 2013, 122, 3607-3615.	1.4	159
116	Successful treatment of pediatric plasmacytoid dendritic cell tumors with a contemporary regimen for acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2013, 60, E38-41.	1.5	8
117	Panobinostat Enhances Cytarabine and Daunorubicin Sensitivities in AML Cells through Suppressing the Expression of BRCA1, CHK1, and Rad51. <i>PLoS ONE</i> , 2013, 8, e79106.	2.5	76
118	Prognostic Factors For Children With Acute Myeloid Leukemia Who Achieve Minimal Residual Disease-Negative Status After Induction Therapy. <i>Blood</i> , 2013, 122, 490-490.	1.4	0
119	Ontogeny and Sorafenib Metabolism. <i>Clinical Cancer Research</i> , 2012, 18, 5788-5795.	7.0	40
120	Longitudinal Changes in Body Mass and Composition in Survivors of Childhood Hematologic Malignancies After Allogeneic Hematopoietic Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2012, 30, 3991-3997.	1.6	52
121	Childhood acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2012, 159, 259-276.	2.5	68
122	Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia. <i>Blood</i> , 2012, 120, 468-472.	1.4	176
123	Comparative Analysis of Different Approaches to Measure Treatment Response in Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2012, 30, 3625-3632.	1.6	188
124	Effect of body mass index on the outcome of children with acute myeloid leukemia. <i>Cancer</i> , 2012, 118, 5989-5996.	4.1	56
125	Treatment outcome in older patients with childhood acute myeloid leukemia. <i>Cancer</i> , 2012, 118, 6253-6259.	4.1	32
126	Combination chemotherapy with clofarabine, cyclophosphamide, and etoposide in children with refractory or relapsed haematological malignancies. <i>British Journal of Haematology</i> , 2012, 156, 275-279.	2.5	16

#	ARTICLE	IF	CITATIONS
127	Longitudinal analysis of antibody response to immunization in paediatric survivors after allogeneic haematopoietic stem cell transplantation. <i>British Journal of Haematology</i> , 2012, 156, 109-117.	2.5	37
128	Pulmonary function after whole lung irradiation in pediatric patients with solid malignancies. <i>Cancer</i> , 2012, 118, 1450-1456.	4.1	29
129	Abstract 2739: Panobinostat potentiates the cytotoxic effects of ara-C and daunorubicin on acute myeloid leukemia cells through suppressing the DNA damage response. , 2012, ,		0
130	Translocation t(6;9)(p22;q34)/DEK-NUP214 rearranged Pediatric AML: A Retrospective International Study. <i>Blood</i> , 2012, 120, 538-538.	1.4	6
131	Parainfluenza Virus Infections in Children With Hematologic Malignancies. <i>Pediatric Infectious Disease Journal</i> , 2011, 30, 855-859.	2.0	38
132	Spinal epidural lipomatosis in children with hematologic malignancies. <i>Annals of Hematology</i> , 2011, 90, 1067-1074.	1.8	10
133	Randomized trial of 2 dosages of prophylactic granulocyte "colony" stimulating factor after induction chemotherapy in pediatric acute myeloid leukemia. <i>Cancer</i> , 2011, 117, 1313-1320.	4.1	13
134	Improved Prognosis for Older Adolescents With Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2011, 29, 386-391.	1.6	122
135	Phase I Pharmacokinetic and Pharmacodynamic Study of the Multikinase Inhibitor Sorafenib in Combination With Clofarabine and Cytarabine in Pediatric Relapsed/Refractory Leukemia. <i>Journal of Clinical Oncology</i> , 2011, 29, 3293-3300.	1.6	142
136	Activity of the Multikinase Inhibitor Sorafenib in Combination With Cytarabine in Acute Myeloid Leukemia. <i>Journal of the National Cancer Institute</i> , 2011, 103, 893-905.	6.3	50
137	Acute Megakaryoblastic Leukemia Without <i>GATA1</i> Mutation After Transient Myeloproliferative Disorder in an Infant Without Down Syndrome. <i>Journal of Clinical Oncology</i> , 2011, 29, e230-e233.	1.6	15
138	Longitudinal Analysis of Body Mass and Composition in Survivors of Pediatric Hematological Malignancies After Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2011, 118, 1991-1991.	1.4	0
139	Combination of cladribine plus topotecan for recurrent or refractory pediatric acute myeloid leukemia. <i>Cancer</i> , 2010, 116, 98-105.	4.1	24
140	Pulmonary dysfunction in survivors of childhood hematologic malignancies after allogeneic hematopoietic stem cell transplantation. <i>Cancer</i> , 2010, 116, 2020-2030.	4.1	53
141	NKAML: A Pilot Study to Determine the Safety and Feasibility of Haploidentical Natural Killer Cell Transplantation in Childhood Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2010, 28, 955-959.	1.6	563
142	Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. <i>Lancet Oncology</i> , The, 2010, 11, 543-552.	10.7	514
143	Glucocorticoid use in acute lymphoblastic leukaemia. <i>Lancet Oncology</i> , The, 2010, 11, 1096-1106.	10.7	282
144	Clinical Activity, Pharmacokinetics, and Pharmacodynamics of Sorafenib In Pediatric Acute Myeloid Leukemia.. <i>Blood</i> , 2010, 116, 1073-1073.	1.4	3

#	ARTICLE	IF	CITATIONS
145	Improved Prognosis for Older Adolescents with Acute Lymphoblastic Leukemia. <i>Blood</i> , 2010, 116, 498-498.	1.4	0
146	Excellent Outcome for ETV6/RUNX1-Positive Childhood Acute Lymphoblastic Leukemia (ALL) with Contemporary Therapy. <i>Blood</i> , 2010, 116, 495-495.	1.4	1
147	Parainfluenza Virus Infections In Children with Cancer. <i>Blood</i> , 2010, 116, 3909-3909.	1.4	0
148	Inhibition of Class I PI3K Isoforms Restores the Sensitivity of Acute Myelogenous Leukemia Cells to Multi-Tyrosine Kinase Inhibitors in the Bone Marrow Microenvironment.. <i>Blood</i> , 2009, 114, 1734-1734.	1.4	0
149	Longitudinal Analysis of Antibody Response to Immunization in Pediatric Survivors After Allogeneic Hematopoietic Stem Cell Transplantation.. <i>Blood</i> , 2009, 114, 795-795.	1.4	0
150	Minimal Residual Diseaseâ€œDirected Therapy for Childhood Acute Myeloid Leukemia: Results of the AML02 Multicenter Trial.. <i>Blood</i> , 2009, 114, 16-16.	1.4	0
151	Pulmonary alveolar proteinosis in pediatric leukemia. <i>Pediatric Blood and Cancer</i> , 2008, 51, 66-70.	1.5	16
152	Clinical and biologic features and treatment outcome of children with newly diagnosed acute myeloid leukemia and hyperleukocytosis. <i>Cancer</i> , 2008, 113, 522-529.	4.1	83
153	Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 1110-1120.	4.1	43
154	In Vivo Suppression of Naive CD4 T Cell Responses by IL-2- and Antigen-Stimulated T Lymphocytes in the Absence of APC Competition. <i>Journal of Immunology</i> , 2008, 181, 3323-3335.	0.8	3
155	Pulmonary Function in Pediatric survivors of non-Malignant Disorders after Allogeneic Hematopoietic Stem Cell Transplantation.. <i>Blood</i> , 2008, 112, 2136-2136.	1.4	1
156	BK Virus-Induced Tubulointerstitial Nephritis in a Child with Acute Lymphoblastic Leukemia. <i>Journal of Pediatrics</i> , 2007, 151, 215-217.	1.8	18
157	Diagnostic Challenge in Recurrent Skin Rash After Autologous Bone Marrow Transplantation. <i>Journal of Pediatric Hematology/Oncology</i> , 2006, 28, 525-528.	0.6	5
158	Allogeneic graft-versus-hepatoblastoma effect. <i>Pediatric Blood and Cancer</i> , 2006, 46, 501-505.	1.5	20
159	Defective cell cycle induction by IL-2 in naive T-cells antigen stimulated in the presence of refractory T-lymphocytes. <i>International Immunology</i> , 2006, 18, 1043-1054.	4.0	20
160	A case of hemoglobin SC disease with cold agglutinin-induced hemolysis. <i>American Journal of Hematology</i> , 2005, 78, 37-40.	4.1	13
161	Acquisition of Fas resistance by Fas receptor mutation in a childhood B-precursor acute lymphoblastic leukemia cell line, MML-1. <i>International Journal of Oncology</i> , 2005, 27, 573.	3.3	3
162	Interferon- γ sensitizes osteosarcoma cells to fas-induced apoptosis by up-regulating fas receptors and caspase-8. <i>Pediatric Blood and Cancer</i> , 2004, 43, 729-736.	1.5	24

#	ARTICLE	IF	CITATIONS
163	Herpes Simplex Virus Pneumonia in a Patient with Ependymoma. Journal of Pediatric Hematology/Oncology, 2004, 26, 108-111.	0.6	4
164	Intracellular cytokine profile of T cells from children with acute lymphoblastic leukemia. Cancer Immunology, Immunotherapy, 2000, 49, 165-172.	4.2	48
165	mRNA expression of variant fas molecules in acute leukemia cells. , 1999, 62, 150-158.		17
166	Epitopes and Functional Responses Defined by a Panel of Anti-Fas (CD95) Monoclonal Antibodies. Hybridoma, 1999, 18, 391-398.	0.6	10
167	mRNA expression of variant fas molecules in acute leukemia cells. American Journal of Hematology, 1999, 62, 150-158.	4.1	1
168	Down-regulation of Fas-Associated Phosphatase-1 (FAP-1) in Interleukin-2-Activated T Cells. Cellular Immunology, 1998, 186, 103-110.	3.0	29
169	Functional Significance of Adhesion Molecules in Fas-Dependent Apoptotic Cell Death Induced by Interleukin-2-Activated T Cells. Immunological Investigations, 1998, 27, 309-322.	2.0	5
170	mRNA expression of Fas receptor (CD95)-associated proteins (Fas-associated phosphatase-1/FAP-1,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 leukaemia/lymphoma cell lines. British Journal of Haematology, 1997, 99, 325-330.	2.5	25
171	Acute myeloid leukemia. , 0, , 395-420.		1
172	Integrated High-Throughput Screen to Identify Novel Treatment Leads for Pediatric Acute Myeloid Leukemia. SSRN Electronic Journal, 0, , .	0.4	0